sST2 adds to the prognostic value of Gal-3 and BNP in chronic heart failure

References

• Sharma UC, Pokharel S, van Brakel TJ, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 2004;110(19):3121–3128.
   PubMed Web of Science ®Google Scholar
• Weinberg EO, Shimpo M, De Keulenaer GW, et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation. 2002;106(23):2961–2966.
   PubMed Web of Science ®Google Scholar
• de Boer RA, Daniels LB, Maisel AS, et al. State of the art: newer biomarkers in heart failure. Eur J Heart Fail. 2015;17(6):559–569.
   PubMed Web of Science ®Google Scholar
• Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23(5):479–490.
   PubMed Web of Science ®Google Scholar
• Sanada S, Hakuno D, Higgins LJ, et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest. 2007;117(6):1538–1549.
   PubMed Web of Science ®Google Scholar
• Weir RAP, Miller AM, Murphy GEJ, et al. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardiol. 2010;55(3):243–250.
   PubMed Web of Science ®Google Scholar
• van der Velde AR, Lexis CPH, Meijers WC, et al. Galectin-3 and sST2 in prediction of left ventricular ejection fraction after myocardial infarction. Clin Chim Acta. 2016;452:50–57.
   PubMed Web of Science ®Google Scholar
• Mueller T, Dieplinger B, Gegenhuber A, et al. Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin Chem. 2008;54(4):752–756.
   PubMed Web of Science ®Google Scholar
• Broch K, Ueland T, Nymo SH, et al. Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology. Eur J Heart Fail. 2012;14(3):268–277.
   PubMed Web of Science ®Google Scholar
• Januzzi JL, Mebazaa A, Di Somma S. ST2 and prognosis in acutely decompensated heart failure: the International ST2 Consensus Panel. Am J Cardiol. 2015;115(7):26B–31B.
   Web of Science ®Google Scholar
• van Kimmenade RR, Januzzi JL, Ellinor PT, et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol. 2006;48(6):1217–1224.
   PubMed Web of Science ®Google Scholar
• Lainscak M, Coletta AP, Sherwi N, et al. Clinical trials update from the Heart Failure Society of America Meeting 2009: FAST, IMPROVE-HF, COACH galectin-3 substudy, HF-ACTION nuclear substudy, DAD-HF, and MARVEL-1. Eur J Heart Fail. 2010;12(2):193–196.
   Web of Science ®Google Scholar
• Lok DJA, Van Der Meer P, de la Porte PWB-A, et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol. 2010;99(5):323–328.
   PubMed Web of Science ®Google Scholar
• Lin Y-H, Lin L-Y, Wu Y-W, et al. The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients. Clin Chim Acta. 2009;409(1–2):96–99.
   PubMed Web of Science ®Google Scholar
• Bayes-Genis A, de Antonio M, Vila J, et al. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3. J Am Coll Cardiol. 2014;63(2):158–166.
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709–717.
   PubMed Web of Science ®Google Scholar
• Filipe MD, Meijers WC, Rogier van der Velde A, et al. Galectin-3 and heart failure: prognosis, prediction and clinical utility. Clin Chim Acta. 2015;443:48–56.
   PubMed Web of Science ®Google Scholar
• Gaggin HK, Motiwala S, Bhardwaj A, et al. Soluble concentrations of the interleukin receptor family member ST2 and beta-blocker therapy in chronic heart failure. Circ Heart Fail. 2013;6(6):1206–1213.
   PubMed Web of Science ®Google Scholar
• Smih F, Desmoulin F, Berry M, et al. Blood signature of pre-heart failure: a microarrays study. PLoS One. 2011;6(6):e20414.
   Web of Science ®Google Scholar
• Koukoui F, Desmoulin F, Galinier M, et al. The prognostic value of plasma galectin-3 in chronic heart failure patients is maintained when treated with mineralocorticoid receptor antagonists. PLoS One. 2015;10(3):e0119160.
   Web of Science ®Google Scholar
• Yin Q-S, Shi B, Dong L, et al. Comparative study of galectin-3 and B-type natriuretic peptide as biomarkers for the diagnosis of heart failure. J Geriatr Cardiol. 2014;11(1):79–82.
   Google Scholar
• Januzzi JL, Peacock WF, Maisel AS Jr, et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol. 2007;50(7):607–613.
   PubMed Web of Science ®Google Scholar
• Aldous SJ, Richards AM, Troughton R, et al. ST2 has diagnostic and prognostic utility for all-cause mortality and heart failure in patients presenting to the emergency department with chest pain. J Card Fail. 2012;18(4):304–310.
   PubMed Web of Science ®Google Scholar
• Anand IS, Rector TS, Kuskowski M, et al. Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT. Eur J Heart Fail. 2013;15(5):511–518.
   PubMed Web of Science ®Google Scholar
• van der Velde AR, Gullestad L, Ueland T, et al. Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH. Circ Heart Fail. 2013;6(2):219–226.
   PubMed Web of Science ®Google Scholar
• Motiwala SR, Szymonifka J, Belcher A, et al. Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. Eur J Heart Fail. 2013;15(10):1157–1163.
   PubMed Web of Science ®Google Scholar
• Weinberg EO, Shimpo M, Hurwitz S, et al. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation. 2003;107(5):721–726.
   PubMed Web of Science ®Google Scholar
• Rehman SU, Mueller T, Januzzi JL Jr. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J Am Coll Cardiol. 2008;52(18):1458–1465.
   PubMed Web of Science ®Google Scholar
• Piper SE, Sherwood RA, Amin-Youssef GF, et al. Serial soluble ST2 for the monitoring of pharmacologically optimised chronic stable heart failure. Int J Cardiol. 2015;178:284–291.
   Web of Science ®Google Scholar
• Ky B, French B, McCloskey K, et al. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail. 2011;4(2):180–187.
   PubMed Web of Science ®Google Scholar
• Bayes-Genis A, Januzzi JL, Gaggin HK, et al. ST2 pathogenetic profile in ambulatory heart failure patients. J Card Fail. 2015;21(4):355–361.
   Web of Science ®Google Scholar
• Bayes-Genis A, Zhang Y, Ky B. ST2 and patient prognosis in chronic heart failure. Am J Cardiol. 2015;115(7):64B–69B.
   Web of Science ®Google Scholar
• Calvier L, Miana M, Reboul P, et al. Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterioscler Thromb Vasc Biol. 2013;33(1):67–75.
   PubMed Web of Science ®Google Scholar
• de Boer RA, Voors AA, Muntendam P, et al. Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail. 2009;11(9):811–817.
   PubMed Web of Science ®Google Scholar
• Yu L, Ruifrok WPT, Meissner M, et al. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail. 2013;6(1):107.
   PubMed Web of Science ®Google Scholar
• Pascual-Figal DA, Lax A, Perez-Martinez MT, et al. Clinical relevance of sST2 in cardiac diseases. Clin Chem Lab Med. 2016;54(1):29–35.
   PubMed Web of Science ®Google Scholar
• deFilippi C, Daniels LB, Bayes-Genis A. Structural heart disease and ST2: cross-sectional and longitudinal associations with echocardiography. Am J Cardiol. 2015;115(7):59B–63B.
   Web of Science ®Google Scholar
• Demissei BG, Valente MAE, Cleland JG, et al. Optimizing clinical use of biomarkers in high-risk acute heart failure patients. Eur J Heart Fail. 2016;18(3):269–280.
   PubMed Web of Science ®Google Scholar
• Lax A, Sanchez-Mas J, Asensio-Lopez MC, et al. Mineralocorticoid receptor antagonists modulate galectin-3 and interleukin-33/ST2 signaling in left ventricular systolic dysfunction after acute myocardial infarction. JACC Heart Fail. 2015;3(1):50–58.
   Web of Science ®Google Scholar
• Azibani F, Benard L, Schlossarek S, et al. Aldosterone inhibits antifibrotic factors in mouse hypertensive heart. Hypertension. 2012;59(6):1179–1187.
   PubMed Web of Science ®Google Scholar
• Calvier L, Martinez-Martinez E, Miana M, et al. The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries. JACC Heart Fail. 2015;3(1):59–67.
   PubMed Web of Science ®Google Scholar
• Koukoui F, Desmoulin F, Lairy G, et al. Benefits of cardiac rehabilitation in heart failure patients according to etiology: INCARD French study. Medicine. 2015;94(7):e544.
   PubMed Web of Science ®Google Scholar
• Gandhi PU, Motiwala SR, Belcher AM, et al. Galectin-3 and mineralocorticoid receptor antagonist use in patients with chronic heart failure due to left ventricular systolic dysfunction. Am Heart J. 2015;169(3):404–411.e3.
   Web of Science ®Google Scholar
• Fiuzat M, Schulte PJ, Felker M, et al. Relationship between galectin-3 levels and mineralocorticoid receptor antagonist use in heart failure: analysis from HF-ACTION. J Card Fail. 2014;20(1):38–44.
   PubMed Web of Science ®Google Scholar
• Maisel A, Xue Y, van Veldhuisen DJ, et al. Effect of spironolactone on 30-day death and heart failure rehospitalization (from the COACH Study). Am J Cardiol. 2014;114(5):737–742.
   PubMed Web of Science ®Google Scholar
• Hernandez AF, Mi X, Hammill BG, et al. Associations between aldosterone antagonist therapy and risks of mortality and readmission among patients with heart failure and reduced ejection fraction. JAMA. 2012;308(20):2097–2107.
   PubMed Web of Science ®Google Scholar
• Zannad F, McMurray JJV, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11–21.
   PubMed Web of Science ®Google Scholar
• Rossignol P, Ménard J, Fay R, et al. Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy. J Am Coll Cardiol. 2011;58(19):1958–1966.
   PubMed Web of Science ®Google Scholar